Skip to main content
TipRanks
Go Ultimate75% OFF

Sonoma Pharmaceuticals (O8Z) AI Stock Analysis

1 Followers
DE:O8Z

Sonoma Pharmaceuticals

(Frankfurt:O8Z)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue growth and narrowing lossesImproving revenue and materially narrower losses indicate that Sonoma’s commercial base is progressing rather than deteriorating. If this trajectory continues, greater scale could help absorb operating costs, support further margin improvement, and move the business closer to sustainable profitability over the next several quarters.
Negative Factors
Persistent unprofitabilityDespite revenue improvement and narrower losses, Sonoma has not yet demonstrated consistently positive earnings. Continued negative margins limit internally generated capital, make the business more dependent on successful execution, and leave profitability vulnerable if growth slows before operating scale improves.

Sonoma Pharmaceuticals (O8Z) vs. iShares MSCI Germany ETF (EWG)

-5%0%5%10%15%20%DE:O8Z0.00%EWG+9.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 4.46M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.9
Beta (1Y)
―
Revenue Growth
―
EPS Growth
―
Country
Germany
Employees
10
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Sonoma Pharmaceuticals Business Overview & Revenue Model

Company Description

Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygien...

Sonoma Pharmaceuticals Risk Analysis

Sonoma Pharmaceuticals disclosed 34 risk factors in its most recent earnings report. Sonoma Pharmaceuticals reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Sonoma Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:O8Z against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AMRXAMRX58Neutral$7.40B49.43131.71%―8.88%2272.07%
PRGOPRGO52Neutral$2.25B-1.27-68.13%7.17%-4.45%-3289.03%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
DERMDERM51Neutral$104.43M-20.28-16.07%―17.03%49.40%
AQSTAQST47Neutral$472.59M-5.88255.11%―12.54%8.82%
ORGOORGO42Neutral$104.24M-0.68-46.25%―-24.33%-1171.44%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:O8ZPRGOORGOAMRXAQSTDERMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:O8Z and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:O8ZSonoma Pharmaceuticals, Inc.2.690.000.00%
PRGOPerrigo Company16.183.9432.23%
ORGOOrganogenesis Holdings0.80-4.72-85.45%
AMRXAmneal Pharma21.239.6683.49%
AQSTAquestive Therapeutics, Inc.3.76-2.15-36.38%
DERMJourney Medical Corporation3.70-4.25-53.46%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.